1283718-57-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-fluoro-4-(hydroxymethyl)benzoate is used as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients for its potential in creating complex molecules.
Used in Organic Chemistry:
Methyl 2-fluoro-4-(hydroxymethyl)benzoate is used as a building block in the creation of complex molecules for its potential in organic chemistry.
Used in Pesticide Industry:
Methyl 2-fluoro-4-(hydroxymethyl)benzoate may be used as a pesticide due to its aromatic nature.
Used in Flavoring Industry:
Methyl 2-fluoro-4-(hydroxymethyl)benzoate may have potential applications as a flavoring agent due to its aromatic nature.

Upstream product

• 67-56-1 methanol 
• 214554-18-4 2-fluoro-4-(hydroxymethyl)benzoic acid 
• 1017598-60-5 (4-bromo-3-fluoro-phenyl)methoxy-tert-butyl-dimethyl-silane 
• 222978-01-0 4-bromo-3-fluorobenzyl alcohol 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 175596-01-7 methyl 4-cyano-2-fluorobenzoate 
• 164149-28-4 4-cyano-2-fluorobenzoic acid 
• 85070-57-1 methyl 4-(bromomethyl)-2-fluoro-benzoate 
• 74733-29-2 2-methyl-3-hydroxybenzoic acid methyl ester 
• 7697-23-6 2-fluoro-4-methylbenzoic Acid 
• 452-74-4 4-bromo-3-fluorotoluene 

Downstream Products

• 85070-58-2 methyl 2-fluoro-4-formylbenzoate 
• 875222-54-1 4-(difluoromethyl)-2-fluorobenzaldehyde 
• 1270981-54-8 methyl 4-(difluoromethyl)-2-fluorobenzoate 

Relevant academic research and scientific papers

NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R1 represents a hydrogen atom, an optionally substituted alkyl group, or the like; R2 represents a hydrogen atom, a halogen atom, or the like; and R3 represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions (by machine translation)

[Problem] imidazole compound or its pharmacologically acceptable salt in the melanocortin receptor activity that operates as an active ingredient of a pharmaceutical composition comprising. "I" general formula [a]" Formula, the aryl group may be substituted A ring represents a; R1 Represents a hydrogen atom, or an alkyl group which may be substituted represented; R2 Represents a hydrogen atom, a halogen atom or represents a; R3 The alkyl group may be substituted " represented by the imidazole compound, its pharmacologically acceptable salt as an active ingredient in a pharmaceutical composition. [Drawing] no (by machine translation)

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein R1. X, m. R2, Y, R3, Z, n, R4. A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their prep

BORON-CONTAINING DIACYLHYDRAZINES

The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.